Description
Global Markets Direct ' s latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides an overview of the Bullous Pemphigoid( Dermatology) pipeline landscape.
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for monthsor years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patientswho are debilitated.
Request a sample of this report @ http:// orbisresearch. com / contacts / request-sample / 171204.
Report Highlights Global Markets Direct ' s Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid( Dermatology), complete with analysis by stage of development, drug target, mechanism of action( MoA), route of administration( RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase a copy of this report @ http:// orbisresearch. com / contact / purchase / 171204. For more information contact sales @ orbisresearch. com
The Bullous Pemphigoid( Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.
Bullous Pemphigoid( Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’ s proprietary databases, company / university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company / university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse Complete Report @ http:// orbisresearch. com / reports / index / bullous-pemphigoid-pipelinereview-h2-2016.
Some points from TOC:
Table of Contents 2 List of Tables 4 www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019